Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on egfr/csf-1/ca ix expression
AssigneePangaea Biotech, S.A.
InventorsRafael Rosell Costa, Miguel Taron Roca
Life of this patent
Estimating the term…
Abstract
The present invention relates to a screening method for classifying and for deciding to apply chemotherapy to patients suffering from non-small-cell lung cancer (NSCLC), based on detecting the levels of EGFR, CSF-1 and CA IX.
Claims15
A method for predicting the survival of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps of:
- a) isolating mRNA from a tumor sample of the patient;
- b) determining the gene expression levels of EGFR, CSF-1 and CA IX genes in the sample;
- and
- c) comparing the expression levels of EGFR, CSF-1 and CA IX genes in the sample with reference values for EGFR, CSF-1 and CA IX expression levels,
- wherein an increased expression of the EGFR and CSF-1 genes and a decreased expression of the CA IX gene with respect to the reference values is indicative that the survival prognosis of said patient will be decreased with respect to patients wherein expression of the EGFR, CSF-1 and CA IX gene is not altered.
A method for predicting the survival of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps of:
- a) isolating mRNA from a tumor sample of the patient;
- b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample;
- and
- c) calculating a risk score on the basis of the expression levels of EGFR, CSF-1 and CA IX genes using the formula [0.93×CSF+1.4×CA IX+1.1×EGFR] wherein CSF, CA IX and EGFR are the z-scores of the expression levels of the CSF-1, CA IX and EGFR genes,
- wherein a risk score higher than 0 is indicative of poor survival.
A method for deciding whether a patient suffering NSCLC should be treated with chemotherapy, which comprises the steps of:
- a) isolating mRNA from a tumor sample of the patient;
- b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample;
- and
- c) comparing the expression levels of EGFR, CSF-1 and CA IX genes in the sample with reference values for EGFR, CSF-1 and CA IX expression levels,
- wherein an increased expression of the EGFR and CSF-1 genes and a decreased expression of the CA IX gene with respect to the reference values is indicative that the patient should be treated with chemotherapy.
A method for deciding whether a patient suffering NSCLC should be treated with chemotherapy, comprising the steps of:
- a) isolating mRNA from a tumor sample of the patient;
- b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample;
- and
- c) calculating a risk score on the basis of the expression levels of EGFR, CSF-1 and CA IX genes using the formula [0.93×CSF+1.4×CA IX+1.1×EGFR] wherein CSF, CA IX and EGFR are the z-scores of the expression levels of the CSF-1, CA IX and EGFR genes,
- wherein a risk score higher than 0 is indicative that the patient should be treated with chemotherapy.
A kit for detecting altered expression of the genes EGFR, CSF-1 and CA IX, which comprises a first pair of primers which is capable of amplifying a region of EGFR, a second pair of primers which is capable of amplifying a region of CSF-1, and a third pair of primers which is capable of amplifying a region of the CA IX gene.
Dependencies are inferred from the claim text.